IMMUNEXT PHARMACEUTICALS
R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.
IMMUNEXT PHARMACEUTICALS is a biotech company in Lebanon, United States, founded in 2016. It has raised $11.4M across 6 rounds, most recently a $3.0M Grant in June 2021.
- Headquarters
- Lebanon, New Hampshire
- Employees
- 11–50
- Founded
- 2016
- Website
- immunext.com
- Total Funding
- $11.4M
- Last Round
- $3.0M GrantJun 2021
- Rounds
- 6
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 6 funding rounds for this company. to use credits for reveals, or explore the API.
About
ImmuNext is a biotech developing immune-based therapeutics for autoimmune disease, cancer, and transplant rejection. Its lead program is a human monoclonal antibody targeting VISTA, an immune checkpoint protein, designed to suppress overactive immune responses in lupus and other autoimmune conditions. The company has formed partnerships with major pharmaceutical firms including Eli Lilly, Sanofi, and Janssen, and has received multiple SBIR/STTR awards from NIH to advance its antibody pipeline.
Funding History
Jun 2021
5 more events
- Grant2018
- Grant2018
- Grant2017
Funding: Grant. Amounts, valuations, and investors where available.
Companies in related industries
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...

Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/immunext-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/immunext-pharmaceuticals" alt="IMMUNEXT PHARMACEUTICALS on Indexed.vc" width="260" height="76" /></a>